Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen (NASDAQ:BIIB) shares experienced a change in market expectations as Cantor Fitzgerald revised the company's price target. The new target has been set at $206.00, a decrease from the previous ...

Of the 102 company launches or series A financings since October 2023, just nine had a woman at the helm, according to a ...

Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1 ...

The Payment Card Industry Data Security Standard’s 4.0 requirements are designed to protect card information from theft or ...

Twenty-five years ago, the bestseller “The Tipping Point” turned Malcolm Gladwell into a household name. Describing “the critical mass, the threshold, the boiling point,” Gladwell illustrates ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

Brightcove's deal is one of several large acquisitions of local technology companies expected to close in 2025. Those include Markforged, which is set to be acquired by Waltham's Nano Dimension, and ...

Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...

Next week brings more inflation data, with both the consumer price index (CPI) and producer price index (PPI) readings for ...

Wall Street trading got off to a mixed start early on Wednesday as share price losses at tech giants Alphabet and AMD put ...